209 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
, including future royalties on product sales from such out-licensing agreements.
Research and Development
Our research and development expenses consist … and clinical development work. We charge all research and development expenses to operations as they are incurred. We expect our research and development
6-K
EX-99.2
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
PROFIT
RESEARCH AND DEVELOPMENT EXPENSES
SALES AND MARKETING EXPENSES
GENERAL AND ADMINISTRATIVE EXPENSES
OPERATING LOSS
NON-OPERATING INCOME (EXPENSES
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
., as well as amortization of intangible assets and cost of goods sold on product sales
Research and development expenses for the first three months … ended March 31,
in USD thousands
REVENUES
COST OF REVENUES
GROSS PROFIT
RESEARCH AND DEVELOPMENT EXPENSES
SALES AND MARKETING EXPENSES
GENERAL
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of market acceptance of APHEXDA; the timing, progress and results of current and future preclinical studies and clinical trials and our research … and development programs; regulatory matters, concerns about our financial position, operations results, litigation, government regulation, developments
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
have been mainly focused on research and development. We have incurred losses since inception, principally as a result of research and development … impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline or continue our
6-K
EX-99
xr3gyr4flk7l
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
F-3
dsjg8
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
beh3zq1vio2d1 q01
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
omtmm67p
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
zvql3td3tyei54 2e56e
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
rjqik9rvy sgvk
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
6pvi9 d20w
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
d2sh5 jw9whtzjfxur
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
g31ll7eb 2rkfpwtfy
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
1pp51gl6 2cqzf
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
f5ju6x etibo
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
vtxlf6 ttjqzqa5chu5
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
ek1jsy
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
2warc0ae3jv7 wgh
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am